Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - chymopapain - withdrawn form

Canada - English - Health Canada

knoll pharma inc. - chymopapain - powder for solution - 4unit - chymopapain 4unit - enzymes

New Zealand - English - Medsafe (Medicines Safety Authority)

knoll australia pty limited - chymopapain 4000 pkat - powder for injection - 4000 pkat - active: chymopapain 4000 pkat

New Zealand - English - Medsafe (Medicines Safety Authority)

boots healthcare new zealand limited - chymopapain 10000 u - solution for injection - 10000 u - active: chymopapain 10000 u

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmotex inc. - chymopapain -

Ireland - English - HPRA (Health Products Regulatory Authority)

aventis behring limited - chymopapain - 5 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

knoll limited - chymopapain - pdr for soln for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - chymopapain - withdrawn form

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - digoxin-specific antibody fragment f(ab) -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - digoxin-specific antibody fragment f(ab) (ovine), quantity: 40 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate - digoxin-specific antibody fragment f(ab) (ovine) digifab is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. consequences of multiple dosing with digifab have not been evaluated.